Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-α Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy.
Asaf TzachorOr RozenSoliman KhatibSophie JensenDorit AvniPublished in: Marine biotechnology (New York, N.Y.) (2021)
An array of infections, including the novel coronavirus (SARS-CoV-2), trigger macrophage activation syndrome (MAS) and subsequently hypercytokinemia, commonly referred to as a cytokine storm (CS). It is postulated that CS is mainly responsible for critical COVID-19 cases, including acute respiratory distress syndrome (ARDS). Recognizing the therapeutic potential of Spirulina blue-green algae (Arthrospira platensis), in this in vitro stimulation study, LPS-activated macrophages and monocytes were treated with aqueous extracts of Spirulina, cultivated in either natural or controlled light conditions. We report that an extract of photosynthetically controlled Spirulina (LED Spirulina), at a concentration of 0.1 µg/mL, decreases macrophage and monocyte-induced TNF-α secretion levels by over 70% and 40%, respectively. We propose prompt in vivo studies in animal models and human subjects to determine the putative effectiveness of a natural, algae-based treatment for viral CS and ARDS, and explore the potential of a novel anti-TNF-α therapy.
Keyphrases
- acute respiratory distress syndrome
- sars cov
- extracorporeal membrane oxygenation
- mechanical ventilation
- rheumatoid arthritis
- coronavirus disease
- endothelial cells
- respiratory syndrome coronavirus
- adipose tissue
- dendritic cells
- randomized controlled trial
- high glucose
- systematic review
- oxidative stress
- high resolution
- high throughput
- human health
- diabetic rats
- risk assessment
- intensive care unit
- climate change
- peripheral blood
- combination therapy
- case report
- case control